Denecimig Clears EMA Bar, But Emicizumab's Entrenchment and Missing Head-to-Head Data Define the Real Battle

CHMP Recommends EU Approval for Novo Nordisk's FREHEMGO in Haemophilia A

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Novo Nordisk's FREHEMGO® (denecimig) for the treatment of haemophilia A, with or without inhibitors, in adults and children. FREHEMGO® is a next-generation FVIIIa mimetic bispecific antibody designed for routine prophylaxis, offering flexible once-monthly, once-every-two-weeks, and once-weekly dosing options in a single-use pre-filled pen. This recommendation is based on the FRONTIER trial program, which demonstrated significant reductions in annualised bleeding rates and a strong safety profile. Novo Nordisk anticipates launching FREHEMGO® in the first European countries in Q4 2026, with broader EU availability starting early 2027.

• The CHMP's positive opinion is supported by the comprehensive FRONTIER trial program, including pivotal FRONTIER 2, FRONTIER 3, and FRONTIER 5 studies. Denecimig consistently demonstrated significant reductions in annualised bleeding rates compared to prior prophylaxis and on-demand treatment, with mean rates generally below 1 and a substantial proportion of participants achieving zero treated bleeds across adult, adolescent, and paediatric populations. FRONTIER 5 also confirmed no new safety signals upon switching from emicizumab.
• FREHEMGO® stands out as the first FVIIIa mimetic to offer a highly flexible dosing regimen, allowing for once-monthly, once-every-two-weeks, or once-weekly administration. This versatility, combined with its delivery via a single-use pre-filled pen, aims to significantly reduce treatment burden and enhance convenience for people living with haemophilia A, providing greater freedom in managing their condition.
• Beyond the positive CHMP recommendation in the EU, Novo Nordisk also submitted denecimig for review to the US Food and Drug Administration (FDA) in September 2025 through a Biologics License Application (BLA). This indicates a broad global strategy for the drug, aiming to make this differentiated treatment option available to patients in major markets worldwide.

Addressing Key Challenges in Haemophilia A Prophylaxis

Despite meaningful advances in Haemophilia A management — from factor replacement to non-factor therapies and gene therapy — significant clinical, immunological, and structural barriers continue to limit optimal outcomes across patient populations. These challenges span treatment burden, immune complications, and access to emerging modalities.

• Inhibitor Development: The formation of inhibitory antibodies to factor VIII (FVIII) remains a major complication of replacement therapy. Risk is influenced by the underlying FVIII gene defect, with null F8 mutations carrying an odds ratio of 2.6 for progression to high-titre inhibitors, and by genetic determinants in the promoter regions of IL-10 and TNFα. Family history of inhibitors (OR: 7.2) and high-dose immune tolerance induction (≥100 IU FVIII concentrate/kg/d; OR: 3.9) are also associated with progression from low- to high-titre inhibitors. Immune tolerance induction (ITI) eliminates inhibitors in 60–80% of cases but is costly, and patients with persistent inhibitors face increased bleeding-related mortality and morbidity alongside reduced quality of life.

• Treatment Burden of Prophylaxis: Standard prophylaxis requires intravenous infusions two to four times per week, imposing a high treatment burden and necessitating reliable intravenous access. The volume of clotting factor required exceeds that of episodic treatment, creating additional logistical and economic strain for patients, families, and healthcare practitioners. These barriers have historically limited the translation of prophylaxis as standard of care into clinical practice, particularly in resource-constrained settings such as South Africa, where more than 2,000 people are diagnosed with Haemophilia A but only a few are currently on prophylaxis.

• Thrombotic Risk with Combination Therapies: In patients with inhibitors receiving emicizumab, concurrent use of activated prothrombin complex concentrate (aPCC) at high or frequent doses has been associated with serious adverse events. In the HAVEN 1 trial, three patients developed thrombotic microangiopathy (TMA) and two developed thrombosis under this combination. When the combination was avoided in HAVEN 2, no patient developed TMA or thrombosis, underscoring the need for careful management of breakthrough bleeding in patients on emicizumab.

• Gene Therapy Eligibility and Durability Limitations: Although AAV-based gene therapies are now approved, eligibility is restricted by preexisting neutralizing antibodies and immune responses to AAV capsids. Factor VIII expression levels in Haemophilia A decline after peaking — in contrast to the more stable factor IX expression seen in Haemophilia B — raising concerns about long-term durability. The difficulty of packaging the oversized FVIII transgene into AAV vectors presents an additional technical constraint. Variable patient outcomes and these eligibility restrictions may contribute to slower adoption despite regulatory approval.

• Musculoskeletal Sequelae from Subclinical Bleeding: Subclinical joint bleeding early in life leads to measurable functional impairments even before overt structural damage is apparent. In a cohort of 273 children with haemophilia (mean age 9.8 years), orthopaedic assessments revealed clinically silent pressure pains in the ligaments of the knee joints in 38% and in the ligaments and capsule of the ankle joints in 60%, alongside significant deficits in fitness, endurance, coordination, and flexibility relative to healthy controls. These findings underscore that even with prophylaxis, early and comprehensive musculoskeletal monitoring is required to prevent irreversible joint damage.

• Access, Reimbursement, and Equity: Key implementation challenges for advanced therapies — including gene therapy — encompass outcome-based reimbursement models, hub-and-spoke treatment infrastructure, and ensuring equitable global access. These systemic barriers risk limiting the real-world benefit of approved innovations to a narrow subset of eligible patients.

FRONTIER Program: Denecimig's Efficacy and Safety Profile

Recent clinical evidence across Haemophilia A spans gene therapy, bispecific antibody prophylaxis, extended half-life factor replacement, and recombinant factor concentrates, collectively illustrating the breadth of therapeutic innovation in this space.

FREHEMGO's Differentiated Role in Haemophilia A Treatment

The treatment landscape for Haemophilia A has undergone substantial transformation, driven by the maturation of non-factor and gene-based therapeutic modalities alongside continued refinement of factor replacement strategies. Emicizumab, a bispecific monoclonal antibody bridging activated factors IXa and X, has demonstrated compelling efficacy across a broad patient spectrum. In the HAVEN 7 phase 3b trial, emicizumab at 3 mg/kg every two weeks produced a model-based annualized bleed rate (ABR) for treated bleeds of 0.4 (95% CI, 0.30–0.63) in infants aged ≤12 months, with 54.5% of participants achieving zero treated bleeds and no intracranial hemorrhage events recorded. In a real-world retrospective cohort of 73 patients with severe Haemophilia A, emicizumab delivered a 100% reduction in ABR for inhibitor-positive patients (from 20.7 to 0.0) and a 99.5% reduction for inhibitor-negative patients (from 7.7 to 0.04), with favorable tolerability. Economic modelling further supports emicizumab's profile, projecting 278.2 cumulative treated bleeds avoided and delayed arthropathy onset (mean age 12.9 vs. 5.4 years) compared with short-acting recombinant FVIII prophylaxis over a lifetime horizon.

Gene therapy has emerged as a particularly consequential development, with valoctocogene roxaparvovec accumulating the most mature clinical evidence. The phase 3 GENEr8-1 trial, now reporting three-year outcomes across 134 adult males, demonstrated that mean annualized bleeding rate for treated bleeds decreased from 4.8 bleeds/year at baseline to 0.97 bleeds/year during year 3, with annualized FVIII utilization reduced by 94.2% during that same period. Mean and median FVIII activity at week 156 were 18.4 (SD, 30.8) and 8.3 IU/dL, respectively, with the rate of FVIII activity decline slowing between years 2 and 3 compared with years 1 and 2. A matching-adjusted indirect comparison against efanesoctocog alfa found that patients treated with valoctocogene roxaparvovec had higher odds of experiencing zero treated bleeds (OR 2.68, 95% CI 1.18–6.14) and zero treated joint bleeds (OR 2.75, 95% CI 1.09–6.86) at 52 weeks. A systematic review and meta-analysis encompassing valoctocogene roxaparvovec, giroctocogene fitelparvovec, and dirloctocogene samoparvovec confirmed that gene therapy reduced ABR versus FVIII prophylaxis (SMD −0.72, 95% CI −0.96 to −0.48; p < 0.00001), with mean FVIII activity reaching 8.3–67.5 IU/dL in year 1 before declining, and FVIII prophylaxis use decreasing by more than 96% by year 4.

Beyond emicizumab and gene therapy, the landscape has also been reshaped by fitusiran, a first-in-class RNA interference therapy targeting antithrombin to rebalance hemostasis independent of factor replacement. In the phase 3 ATLAS-PPX trial, once-monthly 80 mg subcutaneous fitusiran reduced estimated mean ABR by 79.7% (P = .0021) versus prior bypassing agent or clotting factor concentrate prophylaxis in inhibitor-positive participants, with 63.1% of all participants experiencing zero treated bleeds on fitusiran compared with 16.9% on prior therapy. A phase 2 open-label extension study further demonstrated that fitusiran maintained a median ABR of 0.87 on an antithrombin-based dose regimen over a median exposure of 4.1 years, with no thrombotic events following implementation of that regimen and a reduction in elevated transaminase incidence. Collectively, these data reflect a treatment paradigm that has shifted decisively toward factor-independent and one-time interventional approaches, with ongoing surveillance requirements for long-term hepatic safety and thrombotic risk remaining central considerations for clinical and strategic decision-making.

FREHEMGO®'s EU Nod: Reshaping Hemophilia A Prophylaxis

The recent positive opinion from the CHMP for Novo Nordisk's FREHEMGO® (denecimig) marks a pivotal moment for the haemophilia A community in Europe. This recommendation for marketing authorisation, covering both adults and children with or without inhibitors, underscores the potential of this next-generation FVIIIa mimetic bispecific antibody to significantly advance prophylactic care. FREHEMGO® is designed to restore the crucial tenase function, a mechanism that bypasses the deficient Factor VIII, offering a robust solution for bleed prevention.

A key differentiator for FREHEMGO® lies in its patient-centric design. The availability of flexible once-monthly, once-every-two-weeks, and once-weekly dosing options, delivered via a convenient single-use pre-filled pen, represents a substantial leap in treatment convenience. This is further enhanced by a novel tiered dosing strategy, meticulously developed through model-informed drug development, which simplifies administration across various body weight ranges. Such flexibility is critical for improving patient adherence and quality of life, addressing a long-standing challenge in chronic disease management.

However, the path forward is not without considerations.

• One significant aspect is the known interference of FVIIIa mimetics with standard aPTT-based coagulation assays. This necessitates careful selection and interpretation of diagnostic tests, a critical point for healthcare providers managing patients on this therapy, especially during acute bleeding events or surgical procedures.

• Furthermore, while the European launch is anticipated in late 2026, the competitive landscape is dynamic. Existing FVIIIa mimetics are well-established, and the rapid emergence of gene therapies, including those delivering FVIII mimetic antibodies, presents a long-term challenge. These gene therapies promise sustained, potentially life-long haemostatic control, which could reshape the treatment paradigm beyond prophylactic injections.

Novo Nordisk's strategic entry into this advanced segment of haemophilia care, backed by strong clinical data from the FRONTIER program, positions FREHEMGO® as a formidable contender. Its success will hinge on effective market access strategies, comprehensive physician and patient education regarding its unique benefits and diagnostic considerations, and continuous innovation to stay ahead in a field increasingly driven by transformative therapies. This approval signals a continued evolution towards more personalized and less burdensome treatments for haemophilia A.